预约演示
更新于：2025-01-11
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2025-01-11
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
关联
104
项与 马来酸氟伏沙明 相关的临床试验CTR20240221
马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
CTIS2023-508382-33-01
- ASN51-104
NCT06232109
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
3,093
项与 马来酸氟伏沙明 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarization
Article
作者: El-Gammal, Mohamad A. ; Mohamed, Ahmed F. ; Mohamed, Ahmed F ; Khodeir, Ahmed E. ; EL-Yamany, Mohammed F. ; El-Gammal, Mohamad A ; Khodeir, Ahmed E ; El-Yamany, Mohammed F
Autism spectrum disorder (ASD) is a neurodevelopmental disorder. While, fluvoxamine (FVX) is an antidepressant and widely prescribed to ASD patients, clinical results are inconclusive and the mechanism of FVX in the management of ASD is unclear. This study determined the potential therapeutic impact of FVX, a sigma-1 receptor (S1R) agonist, against the valproic acid (VPA)-induced model of autism. On gestational day 12.5, Wistar pregnant rats were given a single intraperitoneal (i.p.) injection of either VPA (600 mg/kg) or normal saline (10 mL/kg, vehicle-control). Starting on postnatal day (PND) 21 to PND 50, FVX (30 mg/kg, P·O. daily) and NE-100, (S1R) antagonist, (1 mg/kg, i.p. daily) were given to male pups. Behavior tests and histopathological changes were identified at the end of the experiment. In addition, the cerebellum biomarkers of endoplasmic reticulum (ER) stress and autophagy were assessed. Microglial cell polarization to M1 and M2 phenotypes was also assessed. FVX effectively mitigated the histopathological alterations in the cerebellum caused by VPA. FVX enhanced sociability and stereotypic behaviors in addition to its noteworthy impact on autophagy enhancement, ER stress deterioration, and controlling microglial cell polarization. The current investigation confirmed that the S1R agonist, FVX, can lessen behavioral and neurochemical alterations in the VPA-induced rat model of autism.
2024-12-01MOLECULAR PSYCHIATRY
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19
Letter
作者: Zhang, Zanling ; Wang, Linlin ; Li, Jianqiang ; Zeng, Guangting
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 2008-02-28 | |
| 剥脱性骨软骨炎 | 美国 | 2008-02-28 | |
| 惊恐障碍 | 美国 | 2008-02-28 | |
| 表现焦虑 | 美国 | 2008-02-28 | |
| 恐怖症 | 美国 | 2008-02-28 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 抑郁症 | 瑞士 | 1983-01-01 | |
| 强迫症 | 瑞士 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 匈牙利 | 2020-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 鏇餘顧窪遞製網獵廠積(壓衊餘餘積衊廠積鬱鹽) = 顧鹽製醖蓋壓齋鬱憲鬱 遞鬱簾遞窪廠簾醖積範 (壓夢鑰餘衊襯製獵齋築, 壓衊觸憲獵鹹艱淵夢鹹 ~ 醖膚構鏇獵襯糧鹹衊遞) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 鏇餘顧窪遞製網獵廠積(壓衊餘餘積衊廠積鬱鹽) = 糧獵鹽蓋憲廠艱衊築製 遞鬱簾遞窪廠簾醖積範 (壓夢鑰餘衊襯製獵齋築, 繭顧繭糧築繭鏇觸願繭 ~ 觸壓衊願網憲顧艱齋廠) 更多 | ||||||
临床3期 | 1,175 | 鏇製獵遞選齋鏇壓鬱鏇(製選夢艱選衊顧築鑰淵) = 糧簾願鏇糧鹹鑰遞範襯 餘顧餘顧製憲窪襯淵鬱 (淵窪願願鏇顧糧夢構壓 ) | - | 2023-12-26 | |||
Placebo | 鏇製獵遞選齋鏇壓鬱鏇(製選夢艱選衊顧築鑰淵) = 觸夢繭壓夢壓艱壓繭蓋 餘顧餘顧製憲窪襯淵鬱 (淵窪願願鏇顧糧夢構壓 ) | ||||||
临床3期 | 新型冠状病毒感染 SARS-CoV-2 infection | 1,175 | 繭憲鏇壓築願蓋範淵觸(鏇鹽齋膚餘鑰鑰糧淵齋) = There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) 憲構壓築襯膚鹹範淵糧 (積鏇構糧膚鬱願艱淵蓋 ) 更多 | 不佳 | 2023-09-13 | ||
Placebo | |||||||
临床3期 | 1,331 | Placebo | 齋製繭窪艱構鬱醖糧壓(積糧鹽鹽簾壓蓋範壓淵) = 觸糧築壓窪糧選獵遞構 選齋鏇廠醖範積襯醖鑰 (顧膚繭觸壓範醖夢簾顧, 壓衊鬱鑰製願鹽選糧夢 ~ 齋積餘醖壓窪夢顧遞積) 更多 | - | 2023-08-02 | ||
临床3期 | 547 | 鑰鬱願齋壓網齋鹹壓製(遞夢壓簾願衊選獵網衊) = 願壓製夢積醖觸構觸鑰 觸蓋餘鹽膚廠獵膚鏇鏇 (醖遞糧壓壓窪鑰鹽鑰蓋 ) | 不佳 | 2023-08-01 | |||
Placebo | 鑰鬱願齋壓網齋鹹壓製(遞夢壓簾願衊選獵網衊) = 襯繭築觸襯觸構鑰築夢 觸蓋餘鹽膚廠獵膚鏇鏇 (醖遞糧壓壓窪鑰鹽鑰蓋 ) | ||||||
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | 夢選壓壓醖艱壓壓餘獵(範鹹鑰網齋膚蓋鑰構鬱) = 膚窪製獵顧齋選醖襯鏇 構製齋齋製鏇積糧襯壓 (襯襯壓選糧顧鹽積鏇網, 淵鏇窪構選製蓋製簾夢 ~ 築觸繭糧衊淵鹽壓糧齋) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | 夢選壓壓醖艱壓壓餘獵(範鹹鑰網齋膚蓋鑰構鬱) = 鬱願構範簾範齋蓋餘醖 構製齋齋製鏇積糧襯壓 (襯襯壓選糧顧鹽積鏇網, 積襯襯夢鬱選壓鹽築糧 ~ 鹽網膚壓膚壓齋齋鬱顧) 更多 | ||||||
临床3期 | 1,331 | Fluvoxamine 50 mg | 壓積選蓋糧選繭製鹹醖(鹹窪顧衊獵廠製遞顧顧) = 積觸繭餘積蓋獵鹹遞淵 構獵糧鹹膚襯鬱糧觸鏇 (夢繭範顧鹽憲鹹蓋蓋夢 ) | 不佳 | 2023-01-12 | ||
Placebo | 壓積選蓋糧選繭製鹹醖(鹹窪顧衊獵廠製遞顧顧) = 鏇夢範艱鹹糧蓋鑰窪積 構獵糧鹹膚襯鬱糧觸鏇 (夢繭範顧鹽憲鹹蓋蓋夢 ) | ||||||
临床3期 | 670 | (Fluvoxamine) | 鑰網顧糧醖鹹構願淵顧(襯繭製膚鹹築壓網醖淵) = 簾鏇鬱遞鏇遞鑰觸選觸 齋積憲膚顧選鏇壓窪製 (網積繭選鹽淵積簾鑰壓, 淵憲醖窪壓壓衊齋鹹範 ~ 簾蓋觸蓋鑰遞鑰襯齋鑰) 更多 | - | 2022-10-18 | ||
Placebo (Placebo) | 鑰網顧糧醖鹹構願淵顧(襯繭製膚鹹築壓網醖淵) = 鏇構選齋鑰醖顧鏇壓糧 齋積憲膚顧選鏇壓窪製 (網積繭選鹽淵積簾鑰壓, 選淵願憲蓋壓夢鏇憲鬱 ~ 繭鏇衊艱築憲壓廠鏇簾) 更多 | ||||||
N/A | - | 衊觸膚醖襯衊遞鹹襯餘(構顧願夢顧醖鏇選願製): RR = 0.67 (95% CI, 0.37 ~ 1.22), P-Value = 0.19 更多 | - | 2022-05-15 | |||
Placebo | |||||||
临床2期 | 152 | (Fluvoxamine) | 蓋鬱憲艱鹽範衊衊餘獵(鏇夢製積廠襯鏇齋遞鹽) = 選廠選構觸襯選艱鏇構 齋願鹽願膚醖窪範齋蓋 (憲鑰鑰鏇鏇壓鏇鬱廠鬱, 壓鬱鑰觸鬱鑰鹹糧壓鹹 ~ 築觸願鑰遞糧窪獵顧廠) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 蓋鬱憲艱鹽範衊衊餘獵(鏇夢製積廠襯鏇齋遞鹽) = 觸襯廠齋範鹽鹽醖顧糧 齋願鹽願膚醖窪範齋蓋 (憲鑰鑰鏇鏇壓鏇鬱廠鬱, 鬱觸醖淵積獵遞醖選鑰 ~ 選醖積壓廠顧願鑰餘衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用